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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
Purified complement 
factor H rapidly 
corrects the syndrome 
caused by its 
deficiency in mice
Complement factor H (CFH) is the major 
regulator of the alternative pathway for 
complement activation. Total deficiency of 
CFH results in uncontrolled C3 activation 
through this pathway, and hence deple-
tion of circulating C3. This syndrome is 
associated with dense deposit disease and 
atypical hemolysis. Unfractionated plasma 
infusion is usually tried, and Fakhouri et 
al., as they report in this issue, used a puri-
fied human CFH (hCFH) to examine its 
efficacy in mice with this gene deleted. 
These knockout mice develop glomeru-
lar basement membrane (GBM) deposits 
similar to the human lesion as well as 
secondary C3 deficiency. When the mice 
were treated with the purified human 
CFH, they rapidly normalized their 
plasma C3, and there was a resolution 
of the GBM deposits. These preclinical 
studies suggest that purified CFH might 
be a useful replacement therapy for CFH 
deficiency in humans. See page 279.
Inhibition of STAT3 
prevents kidney fibrosis
The development of interstitial fibrosis is 
one of the hallmarks of progressive kid-
ney injury during chronic kidney disease. 
The mechanism by which this develops is 
under intensive study, and Pang et al. pro-
vide evidence that activation of the STAT3 
signal transduction pathway is critical for 
this process. They induced renal fibrosis in 
what has now become the standard model 
of unilateral ureteric obstruction, which 
is followed rapidly by fibrosis and com-
plete renal shutdown. They used a newly 
developed STAT3 inhibitor, S3I-201. In 
this model, STAT3 was activated, and 
the drug inhibited its activation. Further-
more, the drug reduced the deposition of 
extracellular matrix proteins and reduced 
the infiltration of inflammatory cells. 
S3I-201 also blocked proliferation of renal 
interstitial cells, inducing their apoptosis. 
Whether inhibition of STAT3 is feasible 
with systemically administered drugs with-
out significant side effects in other organs 
remains to be determined. However, if 
these fears are allayed, this drug has clear 
therapeutic potential. See page 257.
NaHCO3 slows 
progression of chronic 
kidney disease 
in hypertensive 
nephropathy
Correction of acidosis is an important 
idea in preventing the progression of 
renal failure. As they report in this issue, 
Mahajan et al. studied patients diagnosed 
with hypertensive nephropathy whose 
renal function was relatively preserved, 
with a mean estimated glomerular filtra-
tion rate (eGFR) about 50% of normal. 
In a prospective, randomized, controlled 
trial lasting 5 years, the researchers gave 
matched patients daily oral NaHCO3 
while maintaining their antihypertensive 
medications, which included angiogenesis 
blockade. The rate of eGFR decline was 
slower and eGFR was higher in patients 
given sodium bicarbonate than in those 
given placebo or sodium chloride. Pre-
vious studies have shown that acidosis 
induces the expression of endothelin, 
which might be the toxic hormone. Hence, 
the potential for correction of acidosis by a 
cheap and palatable treatment is welcome 
news indeed. See page 303.
